Thierry Delaunoit
Research Subjects
Thierry Delaunoit has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Horber
Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
7 shared publications - Dieter Koeberle
University Clinic of Medical Oncology, University Hospital Bern, Bern, Switzerland
7 shared publications - György Bodoky
St. László Teaching Hospital, Budapest, Hungary
7 shared publications - Karin Rothgiesser
Swiss Group for Clinical Cancer Research (SAKK) Competence Center, Bern, Switzerland
7 shared publications - Markus Joerger
Kantonsspital St. Gallen
7 shared publications - Michael Stahl
12Clinic for Oncology and Hematology, Evang. Kliniken Essen-Mitte, Essen, Germany
7 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Data from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Purpose:We assessed the benefit of adjuvant aspirin in patients with resected phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)–mutated colon cancer.Patients and Methods:This was a phase III, prospective, randomized, placebo-controlled, double-blind, multicenter, and multinational trial. Patients with resected colon cancer stage II and III harboring an activating PIK3CA mutation were included. Because of financial constraints, the trial was prematurely closed. Randomization was 2:1 to aspirin 100 mg versus placebo daily for 3 years. The primary endpoint was disease-free survival (DFS). Secondary endpoints included the time to disease recurrence (TTR), overall survival, and adverse events.Results:Overall, 1,040 patients were screened for PIK3CA mutations, with 112 randomized to aspirin (N = 74) and placebo (N = 38). The median age was 66 years, and 42.9% were female. After a median follow-up of 4 years, 19 DFS events occurred, including 10 in the aspirin and nine in the placebo arm. The HR for DFS was 0.57 [90% confidence interval (CI), 0.27–1.22], in favor of aspirin (P = 0.11). DFS rates at 5 years were 86.5% (90% CI, 77.7%–92.0%) in the aspirin and 72.9% (90% CI, 55.7%–84.3%) in the placebo arm. The HR for TTR was 0.49 (90% CI, 0.21–1.19, P = 0.089) in favor of aspirin. No patient experienced aspirin-related serious adverse events.Conclusions:The SAKK 41/13 is the first randomized trial to provide clinical evidence of a protective effect of adjuvant aspirin in patients with resected PIK3CA-mutant colon cancer, with clinically relevant DFS and TTR improvements. Although results were not statistically significant because of premature study closure, adjuvant aspirin warrants individual consideration in patients with resected PIK3CA-mutant colon cancer stage II and III.See related commentary by Drew et al., p. 3107
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Purpose:We assessed the benefit of adjuvant aspirin in patients with resected phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)–mutated colon cancer.Patients and Methods:This was a phase III, prospective, randomized, placebo-controlled, double-blind, multicenter, and multinational trial. Patients with resected colon cancer stage II and III harboring an activating PIK3CA mutation were included. Because of financial constraints, the trial was prematurely closed. Randomization was 2:1 to aspirin 100 mg versus placebo daily for 3 years. The primary endpoint was disease-free survival (DFS). Secondary endpoints included the time to disease recurrence (TTR), overall survival, and adverse events.Results:Overall, 1,040 patients were screened for PIK3CA mutations, with 112 randomized to aspirin (N = 74) and placebo (N = 38). The median age was 66 years, and 42.9% were female. After a median follow-up of 4 years, 19 DFS events occurred, including 10 in the aspirin and nine in the placebo arm. The HR for DFS was 0.57 [90% confidence interval (CI), 0.27–1.22], in favor of aspirin (P = 0.11). DFS rates at 5 years were 86.5% (90% CI, 77.7%–92.0%) in the aspirin and 72.9% (90% CI, 55.7%–84.3%) in the placebo arm. The HR for TTR was 0.49 (90% CI, 0.21–1.19, P = 0.089) in favor of aspirin. No patient experienced aspirin-related serious adverse events.Conclusions:The SAKK 41/13 is the first randomized trial to provide clinical evidence of a protective effect of adjuvant aspirin in patients with resected PIK3CA-mutant colon cancer, with clinically relevant DFS and TTR improvements. Although results were not statistically significant because of premature study closure, adjuvant aspirin warrants individual consideration in patients with resected PIK3CA-mutant colon cancer stage II and III.See related commentary by Drew et al., p. 3107
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Representativeness of study participants
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Representativeness of study participants
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Sensitivity analyses accounting for non-proportional hazards. Sensitivity analyses accounting for non-proportional hazards using restricted mean survival time. The separating curves over time indicate the benefit of aspirin over placebo on disease-free survival.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Sensitivity analyses accounting for non-proportional hazards. Sensitivity analyses accounting for non-proportional hazards using restricted mean survival time. The separating curves over time indicate the benefit of aspirin over placebo on disease-free survival.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Overall survival. Kaplan-Meier curve of overall survival (including unstratified hazard ratio) – comparison between patients randomized to aspirin (in red) versus placebo (in blue).
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Overall survival. Kaplan-Meier curve of overall survival (including unstratified hazard ratio) – comparison between patients randomized to aspirin (in red) versus placebo (in blue).
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Impact on disease-free survival by number of tablets taken per day in Cox regression analysis
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Impact on disease-free survival by number of tablets taken per day in Cox regression analysis
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Recurrence-free rates including 90% confidence intervals at different time points
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Recurrence-free rates including 90% confidence intervals at different time points
- 11 March 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (15) , 3142-3149
Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Purpose: We assessed the benefit of adjuvant aspirin in patients with resected phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)–mutated colon cancer. Patients and Methods: This was a phase III, prospective, randomized, placebo-controlled, double-blind, multicenter, and multinational trial. Patients with resected colon cancer stage II and III harboring an activating PIK3CA mutation were included. Because of financial constraints, the trial was prematurely closed. Randomization was 2:1 to aspirin 100 mg versus placebo daily for 3 years. The primary endpoint was disease-free survival (DFS). Secondary endpoints included the time to disease recurrence (TTR), overall survival, and adverse events. Results: Overall, 1,040 patients were screened for PIK3CA mutations, with 112 randomized to aspirin (N = 74) and placebo (N = 38). The median age was 66 years, and 42.9% were female. After a median follow-up of 4 years, 19 DFS events occurred, including 10 in the aspirin and nine in the placebo arm. The HR for DFS was 0.57 [90% confidence interval (CI), 0.27–1.22], in favor of aspirin (P = 0.11). DFS rates at 5 years were 86.5% (90% CI, 77.7%–92.0%) in the aspirin and 72.9% (90% CI, 55.7%–84.3%) in the placebo arm. The HR for TTR was 0.49 (90% CI, 0.21–1.19, P = 0.089) in favor of aspirin. No patient experienced aspirin-related serious adverse events. Conclusions: The SAKK 41/13 is the first randomized trial to provide clinical evidence of a protective effect of adjuvant aspirin in patients with resected PIK3CA-mutant colon cancer, with clinically relevant DFS and TTR improvements. Although results were not statistically significant because of premature study closure, adjuvant aspirin warrants individual consideration in patients with resected PIK3CA-mutant colon cancer stage II and III. See related commentary by Drew et al., p. 3107
- 11 March 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (15) , 3142-3149
Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Purpose: We assessed the benefit of adjuvant aspirin in patients with resected phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)–mutated colon cancer. Patients and Methods: This was a phase III, prospective, randomized, placebo-controlled, double-blind, multicenter, and multinational trial. Patients with resected colon cancer stage II and III harboring an activating PIK3CA mutation were included. Because of financial constraints, the trial was prematurely closed. Randomization was 2:1 to aspirin 100 mg versus placebo daily for 3 years. The primary endpoint was disease-free survival (DFS). Secondary endpoints included the time to disease recurrence (TTR), overall survival, and adverse events. Results: Overall, 1,040 patients were screened for PIK3CA mutations, with 112 randomized to aspirin (N = 74) and placebo (N = 38). The median age was 66 years, and 42.9% were female. After a median follow-up of 4 years, 19 DFS events occurred, including 10 in the aspirin and nine in the placebo arm. The HR for DFS was 0.57 [90% confidence interval (CI), 0.27–1.22], in favor of aspirin (P = 0.11). DFS rates at 5 years were 86.5% (90% CI, 77.7%–92.0%) in the aspirin and 72.9% (90% CI, 55.7%–84.3%) in the placebo arm. The HR for TTR was 0.49 (90% CI, 0.21–1.19, P = 0.089) in favor of aspirin. No patient experienced aspirin-related serious adverse events. Conclusions: The SAKK 41/13 is the first randomized trial to provide clinical evidence of a protective effect of adjuvant aspirin in patients with resected PIK3CA-mutant colon cancer, with clinically relevant DFS and TTR improvements. Although results were not statistically significant because of premature study closure, adjuvant aspirin warrants individual consideration in patients with resected PIK3CA-mutant colon cancer stage II and III. See related commentary by Drew et al., p. 3107